Search

Trihexyphenidyl

[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768] … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.

Biotin

A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.

Echinacea purpurea

Miglustat

Miglustat was first developed as an anti-HIV agent in the 1990s. … It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids.

Protamine sulfate

Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps … Despite the relative importance of protamine sulfate's medical indication, the medication can notoriously cause a variety of potentially rare but genuinely severe adverse effects that include systemic

Phenoxyethanol

It is a glycol ether used as a perfume fixative, insect repellent, antiseptic, solvent, preservative, and also as an anesthetic in fish aquaculture. … Phenoxyethanol has been classified as an antimicrobial and preservative by Health Canada [L2623].

Sevoflurane

[A249910] Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.[A249885] … Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia.

Anagrelide

[busulfan], [hydroxyurea]) and may be better tolerated.[A214274] … [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g.

Isatuximab

Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. … [L12099] Along with [daratumumab], another anti-CD38 mAb, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma.

Enasidenib

Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) … This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation.